Anticholinergic treatment in airways diseases

Advances in Therapy

Volumn 26, Issue 10, 2009, Pages 908-919

  Flynn, Robert A ^a   Glynn, Deirdre A ^a   Kennedy, Marcus P ^a  

^a SLIGO UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Anticholinergic; Asthma; Bronchiectasis; Bronchitis; Bronchodilator; Chronic obstructive pulmonary disease; Cystic fibrosis; Emphysema; Ipratropium; Tiotropium

Indexed keywords

ACLIDINIUM BROMIDE; ATROPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTROPIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; ORCIPRENALINE; OXITROPIUM BROMIDE; PLACEBO; QUATERNARY AMMONIUM DERIVATIVE; SALBUTAMOL; SALMETEROL; TELENZEPINE; TIOTROPIUM BROMIDE;

ASTHMA; BLURRED VISION; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; CYSTIC FIBROSIS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; NAUSEA; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMIC DISEASE; TACHYCARDIA; URINE RETENTION; XEROSTOMIA;

ASTHMA; CHOLINERGIC ANTAGONISTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HUMANS; IPRATROPIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 73949151273     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0074-x     Document Type: Review

References (75)

1. B. Disse G.A. Speck K.L. Rominger T.J. Witek Jr R. Hammer 1999 Tiotropium: mechanistical considerations and clinical profile in obstructive lung disease Life Sci 64 457 464 10.1016/S0024-3205(98)00588-8 1:CAS:528:DyaK1MXoslahtA%3D%3D 10069510 (Pubitemid 29066693)
2. N.J. Gross 2004 Tiotropium bromide Chest 126 1946 1953 10.1378/chest.126.6.1946 1:CAS:528:DC%2BD2MXmtValsQ%3D%3D 15596697 (Pubitemid 39644003)
3. The Global Guidelines for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.com/Guidelineitem.asp?l1= 2&12=1&intId=2003. Accessed October 14, 2009.
4. S. Kesten M. Jara C. Wentworth S. Lanes 2006 Pooled clinical trial analysis of tiotropium safety Chest 130 1695 1703 10.1378/chest.130.6.1695 1:CAS:528:DC%2BD2sXptlSltQ%3D%3D 17166984 (Pubitemid 46033421)
5. F. Maltais A. Hamilton D. Marciniuk, et al. 2005 Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD Chest 128 1168 1718 10.1378/chest.128.3.1168 1:CAS:528:DC%2BD28XktVWjsQ%3D%3D 16162703 (Pubitemid 41324392)
6. National Heart Lung and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO workshop report. 2008 publication.
7. G.J. Rodrigo J.A. Castro-Rodriguez 2005 Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis Thorax 60 740 746 1:STN:280:DC%2BD2MvmvVCiug%3D%3D 16055613
8. H. Iwamoto A. Yokoyama N. Shiota, et al. 2008 Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype Eur Respir J 31 1379 1380 10.1183/09031936.00014108 1:STN:280:DC%2BD1czltFWmsQ%3D%3D 18515562
9. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005;(4):CD003428.
10. M.L. Everard A. Bara M. Kurian T.M. Elliott F. Ducharme V. Mayowe 2005 Anticholinergic drugs for wheeze in children under the age of two years Cochrane Database Syst Rev 3 CD001279 16034861
11. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds, Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edition. New York: McGraw-Hill; 1996:141-160.
12. M.A. Courty 1859 Treatment of asthma Edin Med J 5 665
13. P.J. Barnes 2004 Distribution of receptor targets in the lung Proc Am Thorac Soc 1 345 351 10.1513/pats.200409-045MS 1:CAS:528:DC%2BD28XhsFGjsLk%3D 16113456
14. P.J. Barnes 1987 Cholinergic control of airway smooth muscle Am Rev Respir Dis 136 42 45
15. M.R. Littner J.S. Ilowite D.P. Tashkin, et al. 2000 Long-acting bronchodilation with once-daily dosing of tiotropium in stable chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 1136 1142 1:STN:280:DC%2BD3c3isl2itg%3D%3D 10764302
16. S.I. Rennard C.W. Serby M. Ghafouri P.A. Johnson M. Friedman 1996 Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials Chest 110 62 70 10.1378/chest.110.1.62 1:CAS:528:DyaK2sXit1aksbc%3D 8681667
17. R. Casaburi D.A. Mahler P.W. Jones, et al. 2002 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 217 224 10.1183/09031936.02.00269802 1:CAS:528:DC%2BD38XitVKgu7g%3D 11866001 (Pubitemid 34162820)
18. M. Cazzola M.G. Matera 2008 Novel long-acting bronchodilators for COPD and asthma Br J Pharmacol 155 291 299 10.1038/bjp.2008.284 1:CAS:528: DC%2BD1cXhtFKkurfO 18604231
19. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2009;Aug 14 [Epub].
20. J.M. Jansat R. Lamarca G. de Miquel A. Schrödter B. Miletzki M. Gurniak 2009 Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants J Clin Pharmacol 49 1239 1246 10.1177/0091270009336353 1:CAS:528:DC%2BD1MXhtlSktbnM 19592595
21. S. Lu D.D. Parekh O. Kuznetsova, et al. 2006 An oral selective M3 cholinergic receptor antagonist in COPD Eur Respir J 28 772 780 10.1183/09031936.06.00126005 1:CAS:528:DC%2BD28XhtF2rurrJ 16870658 (Pubitemid 46331998)
22. A. Ikeda K. Nishimura H. Koyama T. Izumi 1995 Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease Thorax 50 62 66 10.1136/thx.50.1.62 1:STN:280:DyaK2M7pt12iug%3D%3D 7886652
23. J.E. Scullion 2007 The development of anticholinergics in the management of COPD Int J Chronic Obstruct Pulmon Dis 2 33 40 1:CAS:528:DC%2BD2sXmtlWjsL4%3D
24. D. Ukena C. Wehinger R. Engelstätter V. Steinijans G.W. Sybrecht 1993 The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients Eur Respir J 6 378 382 1:STN:280:DyaK3s3jtFeitw%3D%3D 8472828
25. K.R. Chapman D.M. Mannino J.B. Soriano, et al. 2006 Epidemiology and costs of chronic obstructive pulmonary disease Eur Respir J 27 188 207 10.1183/09031936.06.00024505 1:STN:280:DC%2BD28%2FgtFentQ%3D%3D 16387952 (Pubitemid 43092683)
26. A.D. Lopez K. Shibuya C. Rao, et al. 2006 Chronic obstructive pulmonary disease: current burden and future projections Eur Respir J 27 397 412 10.1183/09031936.06.00025805 1:STN:280:DC%2BD28%2Fmslensw%3D%3D 16452599 (Pubitemid 43180921)
27. P.M. Calverley P. Walker 2003 Chronic obstructive pulmonary disease Lancet 362 1053 1061 10.1016/S0140-6736(03)14416-9 1:STN:280: DC%2BD3svmt1aqsQ%3D%3D 14522537 (Pubitemid 37186885)
28. D.P. Tashkin B. Celli S. Senn, et al. 2008 A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 1543 1554 10.1056/NEJMoa0805800 1:CAS:528:DC%2BD1cXht1WgsrjJ 18836213
29. P.M. Calverley J.A. Anderson B. Celli, et al. 2007 Salmeterol and futicasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 775 789 10.1056/NEJMoa063070 1:CAS:528:DC%2BD2sXhvFKltL0%3D 17314337 (Pubitemid 46294610)
30. N.R. Anthonisen J.E. Connett J.P. Kiley, et al. 1994 Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study JAMA 272 1497 1505 10.1001/jama.272.19.1497 1:STN:280:DyaK2M%2Fls1ejtQ%3D%3D 7966841 (Pubitemid 24340791)
31. W. Vincken J.A. van Noord A.P. Greefhorst, et al. 2002 Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Eur Respir J 19 209 216 10.1183/09031936.02.00238702 1:CAS:528:DC%2BD38XitVKgu7s%3D 11871363 (Pubitemid 34162819)
32. D.P. Tashkin K. Ashutosh E.R. Bleecker, et al. 1986 Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-centre study Am J Med 81 81 90 10.1016/0002-9343(86)90468-7 1:STN:280:DyaL2s%2FntlCqsQ%3D%3D 2947465
33. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994;105:1411-1419.
34. G.L. Colice 1996 Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease Am J Med 100 11S 18S 10.1016/S0002-9343(96)80037-4 1:STN:280:DyaK287ptFagsg%3D%3D 8610712
35. M. Friedman C.W. Serby S.S. Menjoge, et al. 1999 Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Chest 115 635 641 10.1378/chest.115.3.635 1:STN:280:DyaK1M7otF2muw%3D%3D 10084468 (Pubitemid 29129937)
36. P. Chervinsky 1986 Concomitant bronchodilator therapy and ipratropium bromide. A clinical review Am J Med 81 67 73 10.1016/0002-9343(86)90465-1 1:STN:280:DyaL2s%2FntlCqsg%3D%3D 2947463
37. D.E. O'Donnell T. Flüge F. Gerken, et al. 2004 Effects of tiotropium on lung hyperinfation, dyspnoea and exercise tolerance in COPD Eur Respir J 23 832 840 10.1183/09031936.04.00116004 15218994
38. W.T. McNicholas P.M. Calverley A. Lee J.C. Edwards 2004 Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD Eur Respir J 23 825 831 10.1183/09031936.04.00085804 1:CAS:528:DC%2BD2cXlsF2qt7o%3D 15218993
39. S. Singh Y.K. Loke C.D. Furberg 2008 Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA 300 1439 1450 10.1001/jama.300.12.1439 1:CAS:528:DC%2BD1cXhtFKhsrvK 18812535
40. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2009;Jul 10 [Epub].
41. R.G. Barr J. Bourbeau C.A. Camargo F.S. Ram 2006 Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax 61 854 862 10.1136/thx.2006.063271 1:STN:280:DC%2BD28rnvFemtg%3D%3D 16844726 (Pubitemid 44570305)
42. V. Brusasco R. Hodder M. Miravitlles, et al. 2003 Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 58 399 404 10.1136/thorax.58.5.399 1:STN:280:DC%2BD3s3gslajtg%3D%3D 12728159 (Pubitemid 36560942)
43. S.D. Aaron K.L. Vandemheen D. Fergusson, et al. 2007 Tiotropium in combination with placebo, salmeterol, or futicasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial Ann Intern Med 146 545 555 17310045
44. J.A. Wedzicha P.M. Calverley T.A. Seemungal, et al. 2008 The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/futicasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 19 26 10.1164/rccm.200707-973OC 1:CAS:528:DC%2BD1cXht12mt74%3D 17916806
45. K.F. Rabe W. Timmer A. Sagkriotis K. Viel 2008 Comparison of a combination of tiotropium plus formoterol to salmeterol plus futicasone in moderate COPD Chest 134 255 262 10.1378/chest.07-2138 1:CAS:528: DC%2BD1cXhtVOgu7bI 18403672
46. Briggs A, Glick H, Lozano-Ortega G, et al. On behalf of the TORCH investigators. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2009;Aug 28 [Epub].
47. Y. Oba 2009 Cost-effectiveness of salmeterol, futicasone, and combination therapy for COPD Am J Manag Care 15 226 232 19355795
48. A. Chuck P. Jacobs I. Mayers D. Marciniuk 2008 Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease Can Respir J 15 437 443 19107245
49. M. Najafzadeh C.A. Marra M. Sadatsafavi, et al. 2008 Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD Thorax 63 962 967 10.1136/thx.2007.089557 1:STN:280:DC%2BD1cjhsFygtw%3D%3D 18621985
50. Dalal AA, Petersen H, Simoni-Wastila L, Blanchette CM. Healthcare costs associated with initial maintenance therapy with futicasone propionate 250 mug/salmeterol 50 mug combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ. 2009;Oct 15 [Epub].
51. P.J. Barnes 2000 Chronic obstructive pulmonary disease N Engl J Med 27 269 280 10.1056/NEJM200007273430407 (Pubitemid 30490396)
52. G. Tzelepis S. Komanapolli D. Tyler D. Vega A. Fulambarker 1996 Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease Eur Respir J 9 100 103 10.1183/09031936.96.09010100 1:STN:280:DyaK28vjtFamuw%3D%3D 8834341 (Pubitemid 26037532)
53. B.R. O'Driscoll R.J. Taylor M.G. Horsley D.K. Chambers A. Bernstein 1989 Nebulised salbutamol with and without ipratropium bromide in acute airfow obstruction Lancet 1 1418 1420 10.1016/S0140-6736(89)90126-8 2567431
54. J.P. Karpel 1991 Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD Chest 99 871 876 10.1378/chest.99.4.871 1:STN:280:DyaK3M7otl2jtg%3D%3D 1672634
55. Data from National Health Interview Survey, 2006. National Center for Health Statistics. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Available at: www.cdc.gov/asthma/NHIS/06/Data. htm. Accessed October 14, 2009.
56. National Health Interview Survey (NHIS 2006). Hyattsville, MD: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention; 2006.
57. British Thoracic Society Scottish Intercolliegate Guidelines Network. 2008 British guideline on the management of asthma Thorax 63 suppl.4 iv1 iv121 10.1136/thx.2008.097741 (Pubitemid 351692371)
58. F.M. Ducharme G.M. Davis 1998 Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma J Pediatr 133 479 485 10.1016/S0022-3476(98) 70054-X 1:CAS:528:DyaK1cXntFSqurw%3D 9787684 (Pubitemid 28465372)
59. G.J. Rodrigo C. Rodrigo 2002 The role of anticholinergics in acute asthma treatment: an evidence-based evaluation Chest 121 1977 1987 10.1378/chest.121.6.1977 1:CAS:528:DC%2BD38XlsVejuro%3D 12065366 (Pubitemid 34634423)
60. M. Kumaratne G. Gunawardane 2003 Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office Clin Pediatr (Phila) 42 127 132 10.1177/000992280304200205
61. G.J. Browne L. Trieu P. Van Asperen 2002 Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department Crit Care Med 30 448 453 10.1097/00003246-200202000-00030 1:CAS:528:DC%2BD38XislOisL4%3D 11889328
62. N. Goggin C. Macarthur P.C. Parkin 2001 Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation Arch Pediatr Adolesc Med 155 1329 1334 1:STN:280:DC%2BD38%2FivVOluw%3D%3D 11732951
63. J.J. Zorc M.V. Pusic C.J. Ogborn R. Lebet A.K. Duggan 1999 Ipratropium bromide added to asthma treatment in the pediatric emergency department Pediatrics 103 748 752 10.1542/peds.103.4.748 1:STN:280:DyaK1M3gsFartg%3D%3D 10103297 (Pubitemid 29274466)
64. D. Craven C.M. Kercsmar T.R. Myers, et al. 2001 Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma J Pediatr 138 51 58 10.1067/mpd.2001.110120 1:CAS:528:DC%2BD3MXhtF2msrs%3D 11148512 (Pubitemid 32097141)
65. S. Schuh D.W. Johnson S. Callahan G. Canny H. Levison 1995 Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma J Pediatr 126 639 645 10.1016/S0022-3476(95) 70368-3 1:STN:280:DyaK2M3htl2jtA%3D%3D 7699549
66. F. Qureshi J. Pestian P. Davis A. Zaritsky 1998 Effect of nebulized ipratropium on the hospitalization rates of children with asthma N Engl J Med 339 1030 1035 10.1056/NEJM199810083391503 1:CAS:528:DyaK1cXmvV2itr4%3D 9761804 (Pubitemid 28457864)
67. G.J. Rodrigo C. Rodrigo 2000 First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department Am J Respir Crit Care Med 161 1862 1868 1:STN:280:DC%2BD3czhtFCisg%3D%3D 10852758
68. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev. 2004;(3):CD003269.
69. B.J. O'Connor L.J. Towse P.J. Barnes 1996 Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma Am J Respir Crit Care Med 154 876 880 8887578
70. H.W. Park M.S. Yang C.S. Park, et al. 2009 Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response Allergy 64 778 783 10.1111/j.1398-9995.2008.01876.x 1:CAS:528:DC%2BD1MXlvVantb4%3D 19183167
71. A.S. Rebuck H.I. Marcus 1979 SCH 1000 in psychogenic asthma Scand J Respir Dis Suppl 103 186 191 1:STN:280:DyaE1M7lvFemtQ%3D%3D 155297
72. Kennedy MP, Knowles MR. Allied conditions - cystic fibrosis. In: Stockley R, Rennard S, eds. Chronic Obstructive Pulmonary Disease: A Practical Guide to Management. New York: Wiley-Blackwell Publishing; 2007.
73. J.A. Hassan S. Saadiah H. Roslan B.M. Zainudin 1999 Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis Respirology 4 423 426 10.1046/j.1440-1843.1999.00215.x 1:STN:280:DC%2BD3c%2FnslyhtQ%3D%3D 10612580 (Pubitemid 30016295)
74. Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev. 2001;(4):CD002163.
75. Y. Saito A. Azuma T. Morimoto, et al. 2008 Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy Intern Med 47 585 591 10.2169/internalmedicine.47.0568 18379141 (Pubitemid 351936245)